Ignite Creation Date:
2025-12-25 @ 1:13 AM
Ignite Modification Date:
2026-02-25 @ 7:28 PM
Study NCT ID:
NCT02204293
Status:
TERMINATED
Last Update Posted:
2020-08-07
First Post:
2014-07-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Canakinumab for Treatment of Adult-onset Still's Disease
Sponsor:
Charite University, Berlin, Germany
Organization:
Study Overview
Official Title:
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Status:
TERMINATED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Recruitment issues due to marketing authorization of study drug
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONSIDER
Brief Summary:
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2011-001027-20 | EUDRACT_NUMBER | None | View |